Alluvi, formerly BI 4744, presents a notable development in obesity therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling results in clinical https://onlybookmarkings.com/story22012498/alluvi-a-comprehensive-examination-into-the-medication-s-prospects